Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immune Therapeutics Inc (OP:IMUN)

N/A UNCHANGED
Last Price Updated: 12:27 PM EDT, Oct 18, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0930
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Biostax Corp Announces the Passing of Esteemed Director, H. Louis Salomonsky
From Immune Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV
From Immune Therapeutics, Inc.
Via GlobeNewswire

Performance

More News

Read More
News headline image
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH
From Immune Therapeutics, Inc.
Via GlobeNewswire
News headline image
Statera Biopharma Shares Fall After Taking Stake In Holographic Medical Imaging ↗
Via Benzinga
News headline image
Why Are Statera Biopharma Shares Surging Today ↗
Via Benzinga
News headline image
Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies
From Immune Therapeutics, Inc.
Via GlobeNewswire
News headline image
Immune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and Direction
From Immune Therapeutics, Inc.
Via GlobeNewswire
News headline image
Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development
From Immune Therapeutics, Inc.
Via GlobeNewswire
News headline image
Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors
From Immune Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates ↗
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
Via InvestorPlace
News headline image
The 10 Most Shorted Stocks Right Now for Friday, Dec. 17 ↗
Via InvestorPlace

Frequently Asked Questions

Is Immune Therapeutics Inc publicly traded?
Yes, Immune Therapeutics Inc is publicly traded.
What exchange does Immune Therapeutics Inc trade on?
Immune Therapeutics Inc trades on the OTC Traded
What is the ticker symbol for Immune Therapeutics Inc?
The ticker symbol for Immune Therapeutics Inc is IMUN on the OTC Traded
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.